OZEM Roundhill GLP-1 & Weight Loss ETF
ETF on NASDAQ (US) · Actively managed · Listing
Changes appear once four weeks of holdings are on file.
Largest holding: Eli Lilly and Company, 8,083 shares ($11.4M).
| Current positions Top 10 | % of book |
|---|---|
| Eli Lilly and Company LLY $11.4M | 20.5% |
| Novo Nordisk A/S NVO $6.10M | 10.9% |
| Chugai Pharmaceutical Co., Ltd. 4519 $4.02M | 7.2% |
| HanmiPharm 128940 $3.85M | 6.9% |
| Pfizer, Inc. PFE $3.22M | 5.8% |
| Kailera Therapeutics, Inc. KLRA $2.58M | 4.6% |
| Cspc Pharmaceutical Group Limited 1093 $2.57M | 4.6% |
| Jiangsu Hengrui Pharmaceuticals Co Ltd 1276 $2.31M | 4.1% |
| Hansoh Pharmaceutical Group Co Ltd 3692 $2.10M | 3.8% |
| Viking Therapeutics, Inc. VKTX $2.09M | 3.7% |
Slices are % of holdings value.
| Sectors | % of long value |
|---|---|
| Healthcare | 96.2% |
| Unclassified | 3.8% |
| Industries | % of long value |
|---|---|
| Drug Manufacturers - General | 68.8% |
| Biotechnology | 27.4% |
| Unclassified | 3.8% |
Source: the fund's own published holdings, the portfolio of Nov 17, 2026 (roundhillinvestments.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed May 1, 2026.
The Fund seeks to provide capital appreciation.
Principal investment strategies
The Fund is an actively managed exchange-traded fund ("ETF") that pursues its investment objective by seeking to provide exposure to companies involved in the development of pharmaceutical drugs and/or supplements that can be utilized to help individuals lose weight, maintain an ideal weight, and/or maintain body composition during weight loss ("GLP-1 & Weight Loss Drugs"). The Fund will focus its investments in the securities of companies that are the acknowledged leaders in the development of GLP-1 & Weight Loss Drugs, which it defines as those companies that have GLP-1 & Weight Loss Drugs currently undergoing Phase I, Phase II, and/or Phase III of U.S. Food & Drug Administration ("FDA") clinical trials and in securities of companies with GLP-1 & Weight Loss Drugs that have been approved by the FDA ("GLP-1 & Weight Loss Companies"). For non-U.S. companies that are not subject to oversight by the FDA, the Fund may classify such company as a GLP-1 & Weight Loss Company if that company's GLP-1 & Weight Loss Drug is currently undergoing clinical trials subject to regulatory oversight by that company's applicable food and drug regulator or if that company's GLP-1 & Weight Loss Drug has been approved by the company's applicable food and drug regulator. The Fund will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies. In seeking to achieve the Fund's investment objective, the Fund's investment adviser, Roundhill Financial Inc. ("Roundhill" or the "Adviser"), constructs the Fund's portfolio pursuant to its own proprietary security selection methodology. In general, the methodology prioritizes companies with higher levels of "thematic relevance," which is based upon research on individual companies' public disclosures (e.g., 10-K filings, company presentations, capital markets day presentations, etc.) and other publicly available sources (e.g., sell-side research, biotechnology industry publications, drug development pipeline trackers, etc.). The Fund will also only invest in those companies with a minimum market capitalization of $100 million and an average daily trading volume of $500,000. The Adviser rebalances the weighting of the companies comprising the Fund's portfolio on at least a quarterly basis. The Fund may invest in U.S. and non-U.S. companies (including those operating in developed or emerging market countries) through investments in depositary receipts, American Depositary Receipts ("ADRs") or Global Depositary Receipts ("GDRs"), including depositary receipts whose underlying securities are non-voting preferred securities. Such companies will be small-, mid- and large-capitalization issuers. The Fund will concentrate (i.e., invest more than 25% of its total assets) its investments in the industry or group of industries comprising the health care sector. As of March 31, 2026, the Fund had significant investments in European companies. To the extent the Fund invests a significant portion of its assets in a given jurisdiction or investment sector, the Fund may be exposed to the risks associated with that jurisdiction or investment sector. The Fund is classified as "non-diversified" under the Investment Company Act of 1940 (the "1940 Act").
Management and Contact
- Adviser
- Roundhill Financial Inc.
- Sub-adviser
- Exchange Traded Concepts, LLC
- Portfolio managers
-
The individuals primarily responsible for the day-to-day management of the Fund are Timothy Maloney (Roundhill), William Hershey (Roundhill), David Mazza (Roundhill), Andrew Serowik (ETC), Todd Alberico (ETC), Gabriel Tan (ETC) and Brian Cooper (ETC).
Messrs. Serowik, Alberico, Tan and Cooper served as portfolio managers since 2024 and Messrs. Maloney, Hershey and Mazza have served as portfolio managers since 2025.
- Phone
- (855) 561-5728
- [email protected]
Holdings as of Nov 17, 2026
The full portfolio the fund publishes every business day on its website (roundhillinvestments.com). Every line is listed: holdings we could identify link to their page, the rest (cash, options, swaps, private shares, securities we do not carry) are shown as the fund prints them. Short positions are negative. Change is the share count against Nov 16, 2026.
24 lines, 20 linked, weights sum to 99.98% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | LLY 532457108 | Equity | 8,083 | 0 | 20.49% | $ 11.442M |
| Novo Nordisk A/S | NVO 670100205 | Equity | 149,897 | 0 | 10.92% | $ 6.101M |
| Chugai Pharmaceutical Co Ltd | 4519 JP 6196408 | Equity | 87,300 | 0 | 7.20% | $ 4.023M |
| Hanmi Pharm Co Ltd | 128940 KS B613DJ9 | Equity | 11,503 | 0 | 6.90% | $ 3.855M |
| Pfizer Inc | PFE 717081103 | Equity | 113,197 | 0 | 5.77% | $ 3.223M |
| Kailera Therapeutics Inc | KLRA 482931102 | Equity | 211,629 | 0 | 4.62% | $ 2.582M |
| CSPC Pharmaceutical Group Ltd | 1093 HK 6191997 | Equity | 2,560,000 | 0 | 4.61% | $ 2.574M |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 1276 HK BMV9P26 | Equity | 380,200 | 0 | 4.14% | $ 2.309M |
| Hansoh Pharmaceutical Group Co Ltd | 3692 HK BJYKB72 | Equity | 494,000 | 0 | 3.77% | $ 2.104M |
| Viking Therapeutics Inc | VKTX 92686J106 | Equity | 77,574 | 0 | 3.73% | $ 2.085M |
| AstraZeneca PLC | AZN G0593M107 | Equity | 10,026 | 0 | 3.27% | $ 1.827M |
| Ascletis Pharma Inc | 1672 HK BFLTDL2 | Equity | 3,227,000 | 0 | 3.21% | $ 1.795M |
| Zealand Pharma A/S | ZEAL DC B0SDJB4 | Equity | 50,254 | 0 | 3.04% | $ 1.699M |
| Amgen Inc | AMGN 031162100 | Equity | 3,689 | 0 | 3.02% | $ 1.689M |
|
Roche Holding AG
|
ROP SW BTMJD19 | Equity | 3,213 | 0 | 2.79% | $ 1.555M |
| Structure Therapeutics Inc | GPCR 86366E106 | Equity | 85,120 | 0 | 2.77% | $ 1.547M |
| Gubra A/S | GUBRA DC BMZQSP7 | Equity | 27,580 | 0 | 2.10% | $ 1.173M |
| United Laboratories International Holdings Ltd/The | 3933 HK B1P70H9 | Equity | 1,222,000 | 0 | 2.05% | $ 1.143M |
| Innovent Biologics Inc | 1801 HK BGR6KX5 | Equity | 95,000 | 0 | 1.86% | $ 1.039M |
| MBX Biosciences Inc | MBX 55287L101 | Equity | 18,003 | 0 | 1.71% | $ 955.959K |
| Gilead Sciences Inc | GILD 375558103 | Equity | 4,756 | 0 | 1.45% | $ 809.757K |
|
First American Government Obligations Fund 12/01/2031
|
FGXXX 31846V336 | Money market | 398,085.19 | −2,283,550.95 | 0.71% | $ 398.085K |
|
SWISS FRANC
|
CHF CASHCHF | Equity short | -215,321.29 | −398,430.19 | -0.46% | $ -256.625K |
|
Cash & Other
|
CASH&OTHER CASH&OTHER | Cash | 173,610.55 | +1,156,573.14 | 0.31% | $ 173.611K |
Trades Nov 16, 2026 to Nov 17, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
|
SOUTH KOREA WON
|
KRW | Closed | -2,265,723,960 | — | +2,265,723,960 | $ 1.696M |
|
SWISS FRANC
|
CHF | Sold | 183,108.9 | -215,321.29 | −398,430.19 | $ -474.859K |
|
DANISH KRONE
|
DKK | Closed | 668,881.02 | — | −668,881.02 | $ -98.481K |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up